Regentis Biomaterials
Regentis Biomaterials is a tissue repair company focused on developing and commercializing an innovative hydrogel platform for the repair of damaged tissue, especially in orthopedic treatments. Their lead product, GelrinC, is a cell-free, off-the-shelf hydrogel used for knee cartilage repair, aiming to offer effective, simple, and cost-efficient tissue regeneration therapies that improve patient recovery times and quality of life.
Industries
biotechnology
health-care
medical-device
Nr. of Employees
small (1-50)
Regentis Biomaterials
Products
GelrinC
Acellular, off‑the‑shelf biodegradable hydrogel implant for treatment of focal articular cartilage defects in the knee; applied as a liquid, cured in‑situ by UVA to form a conforming scaffold that degrades over months and is intended to be replaced by regenerated cartilage.
GelrinC
Acellular, off‑the‑shelf biodegradable hydrogel implant for treatment of focal articular cartilage defects in the knee; applied as a liquid, cured in‑situ by UVA to form a conforming scaffold that degrades over months and is intended to be replaced by regenerated cartilage.
Expertise Areas
- Regenerative medicine
- Orthopedic cartilage repair
- Hydrogel biomaterials development
- Clinical trial management for implantable devices
Key Technologies
- PEG‑based hydrogel biomaterials
- UV‑initiated in‑situ photopolymerization
- Surface‑erosion biodegradable scaffolds
- Acellular scaffold implant design